双成药业(002693) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥42,761,740.63, a decrease of 47.52% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥8,742,676.77, representing a decline of 294.04% year-on-year[3]. - The net cash flow from operating activities was a negative ¥23,640,127.59, which is an 18.91% increase in cash outflow compared to the previous year[3]. - The basic earnings per share were -¥0.0211, down 291.82% from the same period last year[3]. - The company's net loss for Q1 2024 was not explicitly stated, but retained earnings decreased to CNY -355,701,958.88 from CNY -346,959,282.11[23]. - The operating profit for Q1 2024 was -14,178,627.36 CNY, down from 120,989.11 CNY in Q1 2023[26]. - The company reported a total comprehensive income of -14,193,507.24 CNY for Q1 2024, compared to 104,982.11 CNY in the same period last year[26]. - The basic and diluted earnings per share for Q1 2024 were both -0.0211 CNY, compared to 0.0110 CNY in Q1 2023[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥798,456,832.58, a decrease of 0.60% from the end of the previous year[3]. - Non-current assets totaled CNY 667,355,536.99, slightly down from CNY 668,012,248.28, a decrease of 0.1%[22]. - Total liabilities increased to CNY 294,772,489.85 from CNY 285,602,524.16, marking a rise of 3.9%[23]. Cash Flow and Investments - The company's cash and cash equivalents increased by 1731.23% year-on-year, primarily due to changes in operating, investing, and financing activities[10]. - Total cash and cash equivalents at the end of Q1 2024 amounted to 17,684,279.51 CNY, an increase from 5,920,315.43 CNY at the end of Q1 2023[29]. - Cash inflow from investment activities was 46,581,555.73 CNY, down from 150,408,649.83 CNY in the previous year[28]. - Cash inflow from financing activities was 25,931,612.24 CNY, significantly higher than 4,392,700.00 CNY in Q1 2023[28]. Sales and Expenses - Sales revenue from goods and services decreased by 41.88% year-on-year, attributed to a decline in drug sales and prices[9]. - The company reported a significant reduction in sales expenses, which fell to CNY 14,600,389.33 from CNY 37,202,576.52, a decrease of 60.7%[24]. - The company achieved a 483.08% increase in cash received from borrowings compared to the previous year, due to new bank loans[10]. - Research and development expenses increased to CNY 3,041,458.97 from CNY 2,589,268.35, representing an increase of 17.4%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,723[12]. - Hainan Shuangcheng Investment Co., Ltd. holds 32.75% of shares, totaling 136,516,546 shares, with 32,000,000 shares pledged[12]. - HSP Investment Holdings Limited holds 15.50% of shares, totaling 64,599,379 shares, with 16,210,000 shares pledged[12]. - The company completed the second exercise period of its stock option plan, increasing total share capital from 414,737,000 shares to 416,789,750 shares[15]. Regulatory Approvals and Product Development - The company has received drug registration approvals for several products, including Thymosin Injection in Pakistan and Acetate Liraglutide Injection in China[17][19]. - The company’s subsidiary, Ningbo Shuangcheng, passed the FDA CGMP pre-approval inspection[17]. - The company’s product, Pregabalin Capsules, received drug registration approval from the National Medical Products Administration[19]. Stock Options and Incentives - The company plans to implement a stock option and restricted stock incentive plan, with 205,275 stock options and 210,000 restricted stocks being exercised or released[15][17]. - The company has 75 individuals eligible for stock options in the current exercise period, with the exercise period running from May 8, 2023, to May 3, 2024[15]. - The company’s stock option plan has seen some options canceled due to performance targets not being met, totaling 205,275 options[16].